Recent Updates
Recently added Catalysts
CBLL Positive Sentiment Score: 70/100

Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026

Key Takeaway: Ceribell, Inc. has announced it will report its second quarter 2026 financial results on August 10, 2026. The company will host a conference call at 1:30 p.m. PT to discuss these results. Ceribell specializes in medical technology for neurological conditions and has developed an innovative EEG platform for acute care settings.
Price reaction · baseline $18.43 (2026-07-20 close) · hit after-hours · clean, no other CBLL news in the window
day 0 close · peak
-2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell is focused on transforming neurological diagnosis and management.
  • The Ceribell System is FDA-cleared for critical care use.
  • The upcoming financial results may indicate strong company performance.

Full Press Release Details

SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Monday, August 10, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 10, 2026.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 1880547. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website athttps://investors.ceribell.com/.
About CeriBell, Inc.Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visitwww.ceribell.comor follow the company onLinkedIn.

Investor ContactBrian JohnstonGilmartin GroupInvestors@ceribell.com

Media ContactBrian PricePress@ceribell.com

Frequently Asked Questions

When will Ceribell report its Q2 2026 financial results?

Ceribell will report its Q2 2026 financial results on August 10, 2026.

What time is the conference call for the financial results?

The conference call will begin at 1:30 p.m. PT on August 10, 2026.

How can investors access the conference call?

Investors can access the call by dialing (800) 715-9871 for domestic or (646) 307-1963 for international callers.

What is the Ceribell System used for?

The Ceribell System is used for rapid diagnosis and monitoring of neurological conditions.

Last updated: Jul 20, 2026